Vaccitech Newsroom

Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, today announces that results from ADVANCE, a Phase 1/2 study in metastatic castrate resistant prostate cancer...

Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19 AZD1222 supported by safety and immunogenicity across all adult age groups Vaccitech Ltd, a clinical-stage...

Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation...

Due to exciting expansion across the company, with offices in the UK (headquarters), USA, Italy and Australia, Vaccitech is now recruiting for a Project Manager/Senior Project Manager - Manufacturing, which is an office based role in the UK, full time (37.5 hours per...

Due to exciting expansion across the company, with offices in the UK (headquarters), USA, Italy and Australia, Vaccitech is now recruiting for an Associate Director - Process Development, which is an office and laboratory-based role in the UK. Please see the role...

Due to exciting expansion across the company, with offices in the UK (headquarters), USA, Italy and Australia, Vaccitech is now recruiting for a Senior Scientist - Process Development, which is an office and laboratory-based role in the UK. Please see the role...

Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces that Oxford University’s Jenner Institute and Oxford Vaccine Group have taken the next step towards the discovery of a...

To assist with the coordination and oversight of cross-functional activities to support the Vaccitech portfolio of research and development programmes. All activities carried out within allocated time, and agreed costs in accordance with quality requirements,...

Oxford, UK – Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has dosed the first person in a Phase 1 clinical study to investigate the safety and...

Vaccitech Ltd and the University of Oxford today announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being...